Senseonics (NYSE:SENS) announced preliminary financial results for 2024 as it considers a reverse stock split.

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- (NYSE American: SENS), a medical technology company focused on the ...

May 13, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitor (CGM ...

Senseonics Holdings, Inc. has provided updates ... The Eversense® 365 is a long-term CGM system that provides continuous glucose monitoring for up to a year with a single sensor.

“2024 was a tremendous year for Senseonics, achieving our long-term ... our position in the marketplace through the newly created CGM division of our commercial partner, Ascensia, and our ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

“2024 was a tremendous year for Senseonics, achieving our long-term goal of commercializing ... Additionally, we’ve strengthened our position in the marketplace through the newly created CGM division ...